What is the recommended dosing and titration schedule for Depakote ER (extended‑release divalproex sodium)?

Depakote ER Dosing and Titration

For Depakote ER (extended-release divalproex sodium), initiate at indication-specific starting doses and titrate systematically to therapeutic plasma concentrations of 40–90 µg/mL for mood stabilization or 85–125 µg/mL for acute mania, with the formulation administered once daily as intact tablets that must not be crushed or chewed. 1

Indication-Specific Dosing Protocols

Acute Mania (Bipolar Disorder)

• Initial dose: 25 mg/kg/day administered once daily 1
• Titration strategy: Increase as rapidly as possible to achieve clinical response or target plasma concentration of 85–125 µg/mL 1, 2
• Maximum dose: 60 mg/kg/day 1
• Rapid loading option: 30 mg/kg/day as a single dose achieves therapeutic levels (mean 93.2 µg/mL) within 3 days in most inpatients with acute mania 3, 4
• Clinical response timeline: Significant improvement typically begins by day 3–5 of treatment 2, 4

Complex Partial Seizures

• Initial dose: 10–15 mg/kg/day 1
• Titration schedule: Increase by 5–10 mg/kg/week to achieve optimal clinical response 1
• Target plasma concentration: 50–100 µg/mL 1
• Maximum dose: 60 mg/kg/day 1
• Monitoring threshold: If satisfactory response is not achieved below 60 mg/kg/day, measure plasma levels to confirm therapeutic range 1

Absence Seizures

• Initial dose: 15 mg/kg/day 1
• Titration schedule: Increase at 1-week intervals by 5–10 mg/kg/day until seizure control or limiting side effects occur 1
• Maximum dose: 60 mg/kg/day 1

Migraine Prophylaxis

• Initial dose: 500 mg once daily for 1 week 1
• Target dose: 1,000 mg once daily thereafter 1
• Dose range: 500–1,500 mg/day 5, 6
• Trial duration: Maintain therapeutic dose for 2–3 months before assessing efficacy 5

Conversion from Immediate-Release Divalproex

When converting from delayed-release divalproex to Depakote ER, increase the total daily dose by 8–20% to achieve comparable plasma exposure. 7, 8

• The extended-release formulation has approximately 89% bioavailability relative to delayed-release divalproex 7, 8
• Depakote ER produces lower peak concentrations (Cmax ratio 0.79) but similar trough concentrations (Cmin ratio 0.96) compared to immediate-release formulations 7, 8
• Once-daily Depakote ER reduces peak-to-trough fluctuation by 4.4–6.2-fold compared to once-daily immediate-release divalproex 9

Critical Administration Requirements

• Swallow tablets whole—do not crush or chew 1
• Once-daily dosing only: Depakote ER is specifically formulated for single daily administration 1
• High-dose caution: At total daily doses ≥2,000 mg, only the extended-release formulation should be used once daily; immediate-release formulations dosed once daily at these levels risk toxic peak concentrations >125 mg/L 9

Therapeutic Drug Monitoring

Target Plasma Concentrations

• Mood stabilization (general): 40–90 µg/mL 10, 5
• Acute mania: 85–125 µg/mL 1, 2
• Epilepsy: 50–100 µg/mL 1

Monitoring Schedule

• Baseline: Complete blood count, liver function tests, pregnancy test in individuals of childbearing potential 5
• During titration: Check serum valproate levels when clinical response is inadequate despite adequate dosing 5, 1
• Maintenance: Liver enzyme testing every 3–6 months 5
• Hematologic surveillance: Monitor platelet count and coagulation parameters (PT/PTT) periodically, especially as thrombocytopenia risk increases significantly at trough concentrations >110 µg/mL in females and >135 µg/mL in males 5, 1

Safety Considerations and Adverse Effects

Common Side Effects

• Nausea, somnolence, dizziness, vomiting, gastrointestinal complaints 2, 11
• Weight gain, increased appetite 1, 12
• Sedation and behavioral activation in pediatric populations 12

Serious Risks Requiring Monitoring

• Hepatotoxicity: Greatest risk in children <2 years, especially during first 6 months of treatment 1
• Thrombocytopenia: Risk increases at plasma concentrations >110 µg/mL (females) or >135 µg/mL (males) 1
• Hyperammonemia: Monitor ammonia levels if unexplained lethargy, vomiting, or mental status changes occur 1
• Teratogenicity: Neural tube defects and other congenital malformations; weigh benefits against fetal risk 1
• Pancreatitis: Including fatal hemorrhagic cases; ordinarily discontinue if this occurs 1

Drug Interactions

• Hepatic enzyme inducers (phenytoin, carbamazepine, phenobarbital, rifampin) increase valproate clearance and may require dose adjustment 1
• Monitor concentrations of concomitant antiepileptic drugs (clonazepam, diazepam, lamotrigine, phenobarbital, carbamazepine, phenytoin) as Depakote ER is titrated upward 1

Discontinuation Protocol

• Never discontinue abruptly 5
• Taper gradually over 10–14 days to minimize withdrawal symptoms and seizure risk 10, 5
• After 9 months of treatment for depression, consider dose reduction to reassess need for continued medication 10

Special Populations

Elderly Patients

• Somnolence is common; increase dose slowly with regular monitoring of fluid and nutritional intake 1

Polytherapy Settings

• Toxicity risk increases when combined with other medications; regular serum monitoring is essential 12
• When converting to monotherapy from polytherapy, concomitant antiepileptic drug dosage can be reduced by approximately 25% every 2 weeks, starting at Depakote ER initiation or delayed 1–2 weeks if seizure risk is a concern 1